menu
    • menu
    [{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glecirasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"JAB-3312","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jacobio Pharma \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Jacobio Pharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Peking University Cancer Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Peking University Cancer Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Peking University Cancer Hospital"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glecirasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Shanghai Allist Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Glecirasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jacobio Pharma \/ Shanghai Allist Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Jacobio Pharma \/ Shanghai Allist Pharmaceuticals"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"JAB-BX102","moa":"||CD73","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jacobio Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JAB-2485","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase I","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Binimetinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glecirasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glecirasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JAB-30300","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jacobio Pharma \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Jacobio Pharma

    Menu

    Jacobio Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glecirasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Shanghai Allist Pharmaceuticals

                            Deal Size : $126.6 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Jacobio Licenses KRAS and SHP2 Inhibitors To Allist in China

                            Details : Jacobio has granted the China rights (including mainland China, Hong Kong, Macau, and Taiwan) of KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 to Shanghai Allist.

                            Product Name : JAB-21822

                            Product Type : Other Small Molecule

                            Upfront Cash : $28.1 million

                            August 30, 2024

                            Lead Product(s) : Glecirasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Shanghai Allist Pharmaceuticals

                            Deal Size : $126.6 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glecirasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jacobio Pharma Announced its KRAS G12C Inhibitor Reached the Primary Endpoint

                            Details : JAB-21822 (glecirasib) is a KRAS G12C inhibitor, small molecule drug candidate which is currently being evaluated for the treatment of KRAS G12C mutated pancreatic cancer.

                            Product Name : JAB-21822

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 30, 2024

                            Lead Product(s) : Glecirasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JAB-3312,Glecirasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jacobio Gets China CDE Clearance for Phase III Trial Of SHP2 Plus KRAS G12C Inhibitor

                            Details : JAB-3312 is a highly selective SHP2 allosteric inhibitor, in combination with JAB-21822 (glecirasib), a KRAS G12C inhibitor is being evaluated for first-line NSCLC patients with KRAS G12C mutations.

                            Product Name : JAB-3312

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 18, 2024

                            Lead Product(s) : JAB-3312,Glecirasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JAB-30300

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.

                            Details : JAB-30300 is an orally bioavailable small molecule, P53 Y220C activator, which is being evaluated for the treatment of patients with solid tumors harboring P53 Y220C mutation.

                            Product Name : JAB-30300

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 03, 2024

                            Lead Product(s) : JAB-30300

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glecirasib,JAB-3312

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib fo...

                            Details : JAB-21822 (glecirasib) is a KRAS G12C inhibitor developed by Jacobio and being developed in KRAS G12C-mutated locally advanced or metastatic pancreatic cancer patients.

                            Product Name : JAB-21822

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 08, 2023

                            Lead Product(s) : Glecirasib,JAB-3312

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JAB-3312

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Jacobio Regains Global Rights to SHP2 Inhibitors

                            Details : Through the termination, Jacobio will regain the global rights previously granted to AbbVie for SHP2 inhibitor, JAB-3312, including decision-making authority over all development, commercialization, manufacturing, regulatory activities relating to SHP2 i...

                            Product Name : JAB-3312

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 07, 2023

                            Lead Product(s) : JAB-3312

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glecirasib,JAB-3312

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China

                            Details : Glecirasib is a novel KRAS G12C inhibitor. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors harbouring KRAS G12C mutation, including a pivotal clinical trial int N...

                            Product Name : JAB-21822

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 07, 2023

                            Lead Product(s) : Glecirasib,JAB-3312

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JAB-BX102,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Jacobio Announces Clinical Collaboration To Evaluate CD73 Monoclonal Antibody JAB-BX102 In Combination With KE...

                            Details : Under the terms of the agreement, the clinical study will evaluate the clinical effect of JAB-BX102, a CD73 monoclonal antibody in combination with KEYTRUDA (pembrolizumab), provided by merck, for the treatment of advanced solid tumors.

                            Product Name : JAB-BX102

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            March 22, 2023

                            Lead Product(s) : JAB-BX102,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JAB-2485

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting

                            Details : JAB-2485 is a highly selective small molecule Aurora A inhibitor. Preclinical data show that JAB-2485 is highly selective at biochemical and cellular levels. It has potential to benefit patients with small cell lung cancer and triple-negative breast canc...

                            Product Name : JAB-2485

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 14, 2023

                            Lead Product(s) : JAB-2485

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed

                            Jacobio Pharma

                            China arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glecirasib,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab

                            Details : JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors.

                            Product Name : JAB-21822

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 13, 2022

                            Lead Product(s) : Glecirasib,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth